Table 1 Patient characteristics
Part A | Part B | Total | ||||
|---|---|---|---|---|---|---|
Saracatinib with C+P q3w ( N =24) | Saracatinib with C q3w ( N =21) | Saracatinib with P q3w ( N =27) | Saracatinib with P q1w ( N =24) | Saracatinib with C+P q3w ( N =20) | All patients ( N =116) | |
Mean age, years (range) | 59 (41–77) | 55 (26–71) | 61 (41–75) | 59 (38–71) | 59 (34–73) | 59 (26–77) |
Sex female/male, N | 10/14 | 14/7 | 14/13 | 15/9 | 6/14 | 59/57 |
Primary tumour, N (%) | ||||||
Ovary | 4 (17) | 5 (24) | 2 (7) | 5 (21) | 2 (10) | 18 (16) |
Oesophagus | 2 (8) | 0 | 3 (11) | 4 (17) | 3 (15) | 12 (10) |
Colorectal carcinoma | 4 (17) | 4 (19) | 1 (4) | 1 (4) | 1 (5) | 11 (9) |
Skin/soft tissue | 2 (8) | 1 (5) | 3 (11) | 0 | 5 (25) | 11 (9) |
Lung | 2 (8) | 2 (10) | 2 (7) | 2 (8) | 0 | 8 (7) |
Stomach | 0 | 1 (5) | 3 (11) | 3 (13) | 1 (5) | 8 (7) |
Breast | 1 (4) | 1 (5) | 2 (7) | 1 (4) | 2 (10) | 7 (6) |
Prostate | 2 (8) | 0 | 0 | 0 | 3 (15) | 5 (4) |
Pancreas | 1 (4) | 0 | 1 (4) | 1 (4) | 1 (5) | 4 (3) |
Other | 6 (25) | 7 (33) | 10 (37) | 7 (29) | 2 (10) | 32 (28) |
WHO performance status, N (%) | ||||||
0 | 7 (29) | 7 (33) | 10 (37) | 10 (42) | 8 (40) | 42 (36) |
1 | 15 (63) | 13 (62) | 14 (52) | 12 (50) | 12 (60) | 66 (57) |
2 | 2 (8) | 1 (5) | 3 (11) | 2 (8) | 0 | 8 (7) |
Number of previous chemotherapy regimens | ||||||
Mean±s.d. | 3.2±1.9 | 5.0±3.8 | 3.2±2.6 | 2.7±2.2 | 3.6±2.9 | 3.5±2.8 |
Median (range) | 3 (1–8) | 4 (1–15) | 2 (1–9) | 2 (1–9) | 3 (1–12) | 3 (1–15) |
Previous treatment, N (%) | ||||||
Surgery | 20 (83) | 18 (86) | 21 (78) | 18 (75) | 18 (90) | 95 (82) |
Chemotherapy | 22 (92) | 21 (100) | 26 (96) | 24 (100) | 19 (95) | 112 (97) |
Radiotherapy | 12 (50) | 4 (19) | 14 (52) | 10 (42) | 10 (50) | 50 (43) |
Immunotherapy/hormone therapy | 6 (25) | 7 (33) | 4 (15) | 5 (21) | 7 (35) | 29 (25) |
Other therapy | 7 (29) | 8 (38) | 3 (11) | 2 (8) | 5 (25) | 25 (22) |
